SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Sep 21, 2026	Sep 21, 2026	View filing
4	Sep 14, 2026	Sep 14, 2026	View filing
S-3ASR	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Aug 25, 2026	Aug 25, 2026	View filing
4	Aug 14, 2026	Aug 14, 2026	View filing
4	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 13, 2026	Aug 13, 2026	View filing
144	Aug 12, 2026	Aug 12, 2026	View filing
144	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
SC 13D/A	Aug 12, 2026	Aug 12, 2026	View filing
SC 13D/A	Aug 12, 2026	Aug 12, 2026	View filing
SC 13D/A	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
144	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 10, 2026	Aug 10, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 3, 2026	Aug 3, 2026	View filing
8-K	Jul 31, 2026	Jul 31, 2026	View filing
DEFA14A	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
DEFM14A	Jun 29, 2026	Jun 29, 2026	View filing
PREM14A	Jun 18, 2026	Jun 18, 2026	View filing
4	May 12, 2026	May 12, 2026	View filing
144	May 11, 2026	May 11, 2026	View filing
4	May 8, 2026	May 8, 2026	View filing

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Bridgewater, NJ

8,700 employees

www.amneal.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Chirag K. Patel

View full financials